PDL BioPharma, Inc. PDLI

Other  —  Other
Market cap
—
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19
Revenue
244.30 320.06 198.11 54.76
Revenue Growth
(58.62%) 31.01% (38.10%) (72.36%)
Gross Profit
240.24 289.52 149.65 1.14
Operating Income
129.40 193.78 (50.59) (99.81)
EBT
109.37 184.53 (55.92) (73.74)
Income after Tax
63.66 110.70 (68.86) (70.69)
Net Income Common
63.61 110.75 (68.86) (70.41)
EPS (Diluted)
0.39 0.71 (0.47) (0.59)
Shares (Diluted, Weighted)
164.19 156.26 145.67 118.63
Gross Margin
98.34% 90.46% 75.54% 2.08%
EBIT Margin
52.97% 60.54% (25.54%) (182.29%)
Net Profit Margin
26.04% 34.60% (34.76%) (128.59%)
Free Cash Flow Margin
46.98% 45.80% 20.20% 90.15%
EBITDA
151.46 231.87 (23.46) (82.40)
EBIT
129.40 193.78 (50.59) (99.81)

Show all line items

In millions of $ except per-share values · columns are period end dates